|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brigatinib, approved in May 2016, is an ALK inhibitor specifically indicated for ALK-positive metastatic NSCLC in patients who have progressed on or resistant to crizotinib therapy.
|
31109722 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of the oncogenic fusion-gene EML4-ALK is a current first-line approach for patients with stage IV non-small cell lung cancer.
|
27863497 |
2016 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to test genetic biomarkers used in clinical practice (EGFR, ALK) and candidate biomarkers identified by the French National Cancer Institute (KRAS, BRAF, PIK3CA, HER2) in patients with metastatic non-small-cell lung cancer for whom two tumor samples were available.
|
26968843 |
2016 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study.
|
29844259 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
|
25876560 |
2015 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent clinical trials led to the approval of crizotinib (PF-02341066; Pfizer) by the U.S. Food and Drug Administration for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumors are positive for anaplastic lymphoma kinase (ALK) alterations.
|
23407559 |
2013 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, lorlatinib 100 mg once daily has a unique safety profile to be considered when prescribed, based on the recent U.S. Food and Drug Administration approval, for the treatment of patients with ALK-positive metastatic non-small cell lung cancer previously treated with a second-generation ALK TKI.
|
30890623 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite their remarkable efficacy in metastatic non-small cell lung cancer (NSCLC), EGFR- and ALK-targeted therapies have not been shown to confer any survival benefit in stage III disease, even in subsets of patients with driver mutations.
|
30711973 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib.
|
28979145 |
2017 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified 33 ROS1-positive and 115 ALK-positive patients with stage IV NSCLC.
|
29981925 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
On April 29, 2014, the FDA granted accelerated approval to ceritinib (ZYKADIA; Novartis Pharmaceuticals Corporation), a breakthrough therapy-designated drug, for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
|
25754348 |
2015 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated tumor response rate and survival after crizotinib treatment of patients with advanced NSCLC with ALK activation using both dichotomous immunohistochemical (IHC) staining and FISH.<b>Experimental Design:</b> Patients with stage IV NSCLC treated with crizotinib were selected.Tumor response was assessed.
|
28183714 |
2017 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The combination of platinum compounds and vinorelbine is often used as a first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), without activating EGFR mutations and ALK rearrangement.
|
26220844 |
2015 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The National Comprehensive Cancer Network (NCCN) guidelines for patients with metastatic non-small cell lung cancer (NSCLC) recommend testing for EGFR, BRAF, ERBB2, and MET mutations; ALK, ROS1, and RET rearrangements; and MET amplification.
|
27151654 |
2016 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Only for the small proportion of patients with metastatic NSCLC and genomic-driven tumors with EGFR or anaplastic lymphoma kinase (ALK)-sensitizing mutations (5%-15%), and possibly <i>BRAF</i> mutations and <i>ROS</i> rearrangements, have initial treatment recommendations remained unchanged, with specific tyrosine kinase inhibitors as the preferred therapy.
|
30642913 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
|
26045865 |
2015 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.
|
31346927 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the KEYNOTE-024 trial, pembrolizumab demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) versus Standard-of-Care (SoC) platinum-based doublets for first-line treatment of PD-L1 -positive (≥50%) metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with no EGFR mutations or ALK translocations.
|
30642550 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the role of conventional radiotherapy (RT) and stereotactic body radiotherapy (SBRT) in patients with epidermal growth factor (EGFR)-mutant or anaplastic lymphoma kinase (ALK) rearrangement-positive metastatic non-small cell lung cancer (NSCLC).
|
29275314 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with stage IV NSCLC treated with an ALK inhibitor at the University of Colorado Cancer Center from 2009 through November 2017 were identified retrospectively.
|
30599201 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A high pretreatment PLR is independently associated with poor survival in stage IV NSCLC with MPE and in a subgroup of epidermal growth factor receptor and anaplastic lymphoma kinase wild-type NSCLC.
|
30886226 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rapid progression of metastatic non-small cell lung cancer (NSCLC) after discontinuation of tyrosine kinase inhibitors or anaplastic lymphoma kinase (ALK) inhibitors has been described and is associated with a poor prognosis.
|
30476657 |
2019 |